Aptevo Therapeutics Inc. (NASDAQ:APVO) plans to present its multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, scheduled for November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
The company said its presentation will examine its broader CD40-directed multispecific portfolio and its approach to coordinating innate and adaptive immune activity within the tumour microenvironment.
The presentation is titled “Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity.” It is listed under abstract number 1060, with Michelle Nelson, PhD, et al., identified as presenters.
Aptevo says solid tumours can interfere with anti-tumour immune responses, making it more difficult for the immune system to recognise and attack cancer cells. Its tumour-directed CD40-activating molecules are designed to concentrate immune activation at the tumour and support a broader anti-tumour response.
The company describes its multispecific technology as a way to combine different targeting or immune-modulating functions in one therapeutic molecule. The approach is intended to coordinate tumour-directed immune activity while addressing mechanisms in the tumour microenvironment that can limit cancer immunotherapies.
Mary Janatpour, PhD, Aptevo’s Senior Vice President and Chief Scientific Officer, said the platform is designed to combine complementary mechanisms and engage innate and adaptive immunity at the tumour while seeking to limit systemic immune activation.
Aptevo is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its pipeline candidates are based on the proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies and are intended to engage the immune system through differentiated mechanisms of action.
A copy of the presentation is expected to be placed on the Publications page of Aptevo’s website after the presentation at the meeting.
Aptevo said the announcement contains forward-looking statements concerning its plans and expectations for multispecific therapeutic candidates, their potential benefits, activity, safety, manufacturability and clinical utility, the effectiveness of its platform technologies, manufacturing activities, future scientific presentations, and the expected timing of IND-enabling studies and an IND submission.
The company said these statements are based on its current intentions, beliefs and expectations and involve risks and uncertainties that could cause actual results to differ materially. Aptevo also said forward-looking statements speak only as of the date of the announcement and that it undertakes no obligation to update them except as required by law.
Aptevo Therapeutics Inc. announced that it will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation will cover Aptevo’s broader CD40-directed multispecific portfolio and its approach to combining innate and adaptive immunity within the tumour microenvironment.
Aptevo Therapeutics Inc. said its presentation will take place at the SITC 2026 Annual Meeting from November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
Aptevo Therapeutics Inc. will present work titled “Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity.” The abstract number is 1060.
Michelle Nelson, PhD, et al will present Aptevo Therapeutics Inc.’s work at the SITC 2026 Annual Meeting.
Aptevo Therapeutics Inc. is developing multispecific antibody-like molecules designed to combine multiple distinct targeting or immune-modulating functions within a single therapeutic. The company says the approach is intended to enable coordinated, tumour-directed immune activity while addressing mechanisms in the tumour microenvironment that can limit cancer immunotherapies.
Aptevo Therapeutics Inc. says its approach combines tumour targeting with localised CD40 and T cell activation to engage both innate and adaptive immunity at the tumour. The company says its tumour-directed CD40-activating molecules are designed to localise immune activation to the tumour and promote a more complete anti-tumour response.
Aptevo Therapeutics Inc. says solid tumours can suppress or disrupt anti-tumour immune responses, limiting the immune system’s ability to recognise and attack cancer. Its multispecific platform is intended to address mechanisms within the tumour microenvironment that can limit the effectiveness of cancer immunotherapies.
Mary Janatpour, PhD, Aptevo Therapeutics Inc.’s Senior Vice President and Chief Scientific Officer, said the technology is designed to bring complementary mechanisms together in a single molecule and create a deeper immune response within the tumour microenvironment. She also said the company is seeking to limit systemic immune activation while engaging innate and adaptive immunity at the tumour.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel multispecific immunotherapies for the treatment of cancer. Its pipeline candidates are created from its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies.
Aptevo Therapeutics Inc. identifies itself as trading under NASDAQ:APVO in the announcement and as Nasdaq:APVO in its company description.
Aptevo Therapeutics Inc. said a copy of the presentation will be made available on the Publications page of its website following the presentation at the meeting.
Aptevo Therapeutics Inc. identifies forward-looking statements covering plans and expectations for its multispecific therapeutic candidates, their potential benefits and clinical utility, the effectiveness of the ADAPTIR™ and ADAPTIR-FLEX™ platforms, manufacturing activities, future scientific presentations, and the expected timing of IND-enabling studies and an IND submission. The company says these statements involve risks and uncertainties that could cause actual results to differ materially.